Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2159 | Nitric Oxide Wiki | 0.50 |
drug2448 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D011024 | Pneumonia, Viral NIH | 0.11 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D055371 | Acute Lung Injury NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 morbidity and mortality has been associated with Cytokine Release Syndrome (CRS) and Acute Respiratory Distress Syndrome (ARDS). ATI-450 is an oral small molecule MAPKAPK2 (MK2) inhibitor that potently inhibits multiple inflammatory cytokines. The investigator hypothesizes that MK2 pathway blockade during active COVID-19 infection in hospitalized participants will result in improvement in respiratory-failure free survival.
Description: Participants medical record
Measure: Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450 Time: Study day 14Description: Using World Health Organization (WHO) COVID-19 Ordinal scale measuring: Proportion and time to participants with greater than 2 point improvement on the 7 point categorical scale. This scale measures illness severity over time and has a range of 0-7. 0- Uninfected: No clinical or virological evidence of infection. 1- Ambulatory: No limitation of activities. 2- Ambulatory: Limitation of activities. 3- Hospitalized, mild disease: Hospitalized, no oxygen. 4- Hospitalized, mild disease: Oxygen by mask or nasal prongs. 5- Hospitalized, severe disease: Non- invasive ventilation or high- flow oxygen. 6- Hospitalized, severe disease: Intubation and mechanical ventilation. 7- Hospitalized, severe disease: Ventilation + organ support; pressors, Renal Replacement Therapy (RRT), Extracorporeal Membrane Oxygenation (ECMO).
Measure: Change in 7 point-ordinal scale Time: Baseline, Day 7, Day 14, Day 28 and follow-up up to 9 monthsDescription: Peripheral capillary pulse oximeter to measure: Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) ratio over time, sustainment of normalization in 24 hours, and relative shifts in SpO2/FiO2 categories (<235, between 235 and 315, greater than 315) over time
Measure: Change in oxygen saturation-normalization Time: Baseline and continuous throughout hospitalization up to 14 daysDescription: Derived from medical record
Measure: Need for advanced respiratory care Time: Baseline and continuous throughout hospitalization up to 14 daysDescription: Noted in participant medical record
Measure: All-cause mortality Time: Baseline and through day 60Description: CTCAE v5.0
Measure: Percentage of adverse events (AEs) Time: Baseline through day 14 or at dischargeDescription: CTCAE v5.0
Measure: Percentage of serious adverse events (SAEs) Time: Baseline through day 14 or at dischargeDescription: Standard daily temperature measurement and obtained from participant medical record
Measure: Proportion of participants with normalization of fever for 24 hours Time: Baseline through day 14 or at dischargeDescription: Noted in participant medical record
Measure: Number of participants who develop new bacterial infection Time: Continuous throughout hospitalization up to 14 daysDescription: Noted in participant medical record
Measure: Number of participants who develop new fungal infection Time: Continuous throughout hospitalization up to 14 daysDescription: Noted in participant medical record
Measure: Incidence of Adult Respiratory distress Syndrome (ARDS2) Time: From day 1 though day 14 or at dischargeDescription: Serum collected from blood and assayed on Luminex panel performed by University of Kansas Medical Center (KUMC) Biobanking and Biomarker Validation (BBV) Core
Measure: Change in serum cytokine Interleukin (IL)-6 Time: Baseline, day 3, day 7 (or dischargeDescription: Serum collected from blood and assayed on Luminex panel performed by KUMC BBV Core
Measure: Change in serum cytokine IL-8 Time: Baseline, day 3, day 7 (or dischargeDescription: Serum collected from blood and assayed on Luminex panel performed by KUMC BBV Core
Measure: Change in serum cytokines IL-1β Time: Baseline, day 3, day 7 (or dischargeDescription: Serum collected from blood and assayed on Luminex panel performed by KUMC BBV Core
Measure: Change in serum cytokine Tumor Necrosis Factor (TNF-α) Time: Baseline, day 3, day 7 (or dischargeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports